Radiology Business January 13, 2025
Drugmaker Lantheus Holdings Inc. has inked a deal to acquire PET agent developer Life Molecular Imaging in a deal worth up to $750 million, the two announced Monday.
The Bedford, Massachusetts, radiopharma firm has signed a “definitive” agreement to buy its rival in an all-cash transaction. Lantheus plans to issue an upfront sum of $350 million and another $400 million in potential earn-out and milestone payments.
Life Molecular Imaging is the maker of Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s. The Berlin, Germany, company also has “robust” research and development capabilities, a “strong” commercial infrastructure, and “established” international presence.
“This acquisition aligns with our strategy to drive long-term...
Today's Sponsors
Today's Sponsor